COST UTILITY ANALYSIS OF HPV VACCINATION WITH BIVALENT AS04 ADJUVANT VACCINE IN SLOVAKIA AND IMPACT OF VACCINE PROTECTION DURATION ON COST-EFFECTIVENESS ENDPOINTS

被引：0
|
作者：
Bielik, J. [1 ]
Foltan, V [2 ]
Psenkova, M. [3 ]
Hroncova, D. [4 ]
Marusakova, E. [5 ]
Sadovsky, O. [6 ]
机构：
[1] Fac Hlth, Trencin, Slovakia
[2] Comenius Univ, Bratislava, Slovakia
[3] Spol S Ro, Pharm In, Bratislava, Slovakia
[4] GSK, Noncommercial Educ Ctr, Bratislava, Slovakia
[5] GlaxoSmithKline Slovakia, Bratislava, Slovakia
[6] Natl Oncol Inst, Bratislava, Slovakia
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(11)73257-0
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A541 / A542
页数：2
相关论文
共 50 条
  • [1] Cost-effectiveness of nonavalent vs bivalent HPV vaccine in Polish setting
    Jakubczyk, Michal
    Bieganska, Joanna
    Kowalczuk, Katarzyna
    Jaworski, Rafal
    Czech, Marcin
    Pavelyev, Andrew
    Daniels, Vincent
    Niewada, Maciej
    GINEKOLOGIA POLSKA, 2025, 96 (02) : 119 - 125
  • [2] QUADRIVALENT HPV VACCINE IN ARGENTINA: COST-EFFECTIVENESS ANALYSIS
    Caporale, J.
    Alcaraz, A.
    Rey-Ares, L.
    Pichon-Riviere, A.
    Bardach, A.
    Augustovski, F.
    Klein, K.
    Tatti, S.
    VALUE IN HEALTH, 2014, 17 (03) : A273 - A273
  • [3] Impact of vaccine protection against multiple HPV types on the cost-effectiveness of cervical screening
    Coupe, Veerle M. H.
    Bogaards, Johannes A.
    Meijer, Chris J. L. M.
    Berkhof, Johannes
    VACCINE, 2012, 30 (10) : 1813 - 1822
  • [4] Universal vaccination with the quadrivalent HPV vaccine in Austria: impact on virus circulation, public health and cost-effectiveness analysis
    Bresse, Xavier
    Goergen, Christoph
    Prager, Bernhard
    Joura, Elmar
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (02) : 269 - 281
  • [5] The projected cost-effectiveness and budget impact of HPV vaccine introduction in Ghana
    Vodicka, Elisabeth
    Nonvignon, Justice
    Antwi-Agyei, Kwadwo Odei
    Bawa, John
    Clark, Andrew
    Pecenka, Clint
    LaMontagne, D. Scott
    VACCINE, 2022, 40 : A85 - A93
  • [6] COST-EFFECTIVENESS ANALYSIS OF UNIVERSAL VACCINATION WITH PENTAVALENT VACCINE IN RUSSIA
    Rudakova, A.
    Ugrekhelidze, D.
    Sharomi, O.
    Cook, J.
    Nachbar, R.
    Lobzin, Y.
    Briko, N.
    Namazova-Baranova, L.
    Podkolzin, A.
    Chen, Y. H.
    VALUE IN HEALTH, 2020, 23 : S545 - S546
  • [7] Potential health impact and cost-effectiveness of bivalent human papillomavirus (HPV) vaccination in Afghanistan
    Anwari, Palwasha
    Debellut, Frederic
    Vodicka, Elisabeth
    Clark, Andrew
    Farewar, Farhad
    Zhwak, Zubiada A.
    Nazary, Dastagger
    Pecenka, Clint
    LaMontagne, D. Scott
    Safi, Najibullah
    VACCINE, 2020, 38 (06) : 1352 - 1362
  • [8] IMPACT OF VACCINATION COVERAGE ON COST-EFFECTIVENESS OF INFLUENZA VACCINE AT PREVENTING HOSPITALIZATION
    You, J.
    VALUE IN HEALTH, 2013, 16 (03) : A92 - A92
  • [9] Cost-effectiveness of Interventions to Increase HPV Vaccine Uptake
    Spencer, Jennifer C.
    Brewer, Noel T.
    Trogdon, Justin G.
    Weinberger, Morris
    Coyne-Beasley, Tamera
    Wheeler, Stephanie B.
    PEDIATRICS, 2020, 146 (06)
  • [10] Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy
    Mennini, Francesco Saverio
    Bonanni, Paolo
    Bianic, Florence
    de Waure, Chiara
    Baio, Gianluca
    Plazzotta, Giacomo
    Uhart, Mathieu
    Rinaldi, Alessandro
    Largeron, Nathalie
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2017, 15
12345